背景对疫苗(ChAdOx1-nCOV;Covishield和BBV-152;Covaxin)对抗2019年冠状病毒病(COVID-19)的有效性进行评估是必要的。因为大多数中和冠状病毒的抗体都针对病毒刺突蛋白内的受体结合域,这些抗体作为标记的病毒中和剂,反过来,疫苗反应。本研究旨在评估针对严重急性呼吸道综合症冠状病毒2(SARS-CoV-2)的疫苗接种时间表(两种疫苗)完成后的抗中和抗体(受体结合域(RBD))和免疫球蛋白G2(IgG2)滴度。方法论在这项纵向前瞻性研究中,在三级护理中心进行,对年龄在18至44岁之间的30名连续(两剂)接种疫苗的研究参与者进行取样以估计抗RBD抗体滴度和IgG2。所有统计分析均使用SPSS第20版(IBMCorp.,Armonk,NY,美国)。P值小于0.05被认为是显著的。结果第二次给药1个月后,中和抗体滴度有统计学上的显着增加(z=-4.597,p<0.001),而IgG2水平显着下降(z=-3.075,p=0.002)。结果表明,所使用的疫苗具有显著的中和作用,Covishield比Covaxin更有效。中和抗体水平独立于所有人口统计学变量,如年龄,性别,和体重指数。结论本研究评估了两种疫苗的疗效,即,Covishield和Covaxin,是恰蒂斯加尔邦同类中的第一个。这项研究的结果与以前在印度和印度以外进行的研究相似,结论Covishield是一种更有效的疫苗。
Background The evaluation of the effectiveness of the vaccines (ChAdOx1-nCOV; Covishield and BBV-152; Covaxin) against coronavirus disease 2019 (COVID-19) is necessary to assess their efficacy. Because most antibodies that neutralize the coronavirus are directed against the receptor binding domain within the spike protein of the virus, these antibodies serve as markers for viral neutralizers and, in turn, for vaccine response. The present study aimed to evaluate the anti-neutralizing antibody (receptor binding domain (RBD)) and immunoglobulin G2 (
IgG2) titers following the completion of the vaccination schedule (both vaccines) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methodology In this longitudinal prospective study, conducted in a tertiary care center, 30 sequentially (two doses) vaccinated study participants between the ages of 18 and 44 years were sampled for estimation of anti-RBD antibody titer and
IgG2. All statistical analysis was done using SPSS version 20 (IBM Corp., Armonk, NY, USA). P-values less than 0.05 were considered significant. Results There was a statistically significant increase in the neutralizing antibody titer after one month of the second dose (z = -4.597, p < 0.001), while a significant decrease was seen in the
IgG2 levels (z = -3.075, p = 0.002). The results showed a significant neutralizing effect of the vaccines being used, with Covishield being more effective than Covaxin. The levels of neutralizing antibodies were independent of all demographic variables such as age, sex, and body mass index. Conclusions This study evaluating the efficacy of the two vaccines, namely, Covishield and Covaxin, is the first of its kind in the state of Chhattisgarh. The results of this study are similar to previous studies conducted in India and outside India, concluding that Covishield is a more effective vaccine.